Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

BACKGROUND. The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Reardon, David A., Lassman, Andrew B., van den Bent, Martin, Kumthekar, Priya, Merrell, Ryan, Scott, Andrew M., Fichtel, Lisa, Sulman, Erik P., Gomez, Erica, Fischer, JuDee, Lee, Ho-Jin, Munasinghe, Wijith, Xiong, Hao, Mandich, Helen, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle D., Gan, Hui K.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Clinical Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570193/
https://ncbi.nlm.nih.gov/pubmed/28039367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now257
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares